Tobacco smoking protective effect via remote ischemic preconditioning on myocardial damage after elective percutaneous coronary intervention: Subanalysis of a randomized controlled trial

RINC Study Collaborators

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Remote ischemic preconditioning (RIPC) is promising for preventing periprocedural myocardial damage (pMD) in patients undergoing percutaneous coronary intervention (PCI). However, the impact of RIPC on pMD on smokers is not well elucidated. The aim of this study was to investigate an association between tobacco smoking and RIPC on pMD in patients planning to undergo PCI. Methods: This study used data from a multicenter randomized controlled trial involving patients with stable angina who planned to undergo elective PCI. We analyzed data for 262 patients in the control (n = 133) and upper-limb RIPC (n = 129) groups, including 166 current or former smokers. The major outcome was the pMD incidence following PCI, with pMD defined as an elevated level of highly sensitive cardiac troponin T or a creatine kinase myocardial band 12 or 24 h after PCI. Results: The incidence of pMD was significantly lower in the upper-limb RIPC group than in the control group (28/83 patients [33.8%] vs. 43/83 patients [51.8%], respectively; p = 0.018). In a multiple logistic regression model, tobacco smoking was an independent predictor of interacting with and enhancing the effect of RIPC on reducing the incidence of pMD after PCI (regression coefficient, −0.4 [95% confidence interval, −0.74 to −0.082]; p = 0.015). Conclusions: Tobacco smoking may have a beneficial effect on RIPC against pMD after PCI.

Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalIJC Heart and Vasculature
Volume22
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Myocardial Ischemic Preconditioning
Ischemic Preconditioning
Percutaneous Coronary Intervention
Randomized Controlled Trials
Smoking
Upper Extremity
Incidence
Logistic Models
MB Form Creatine Kinase
Troponin T
Stable Angina
Confidence Intervals
Control Groups

Keywords

  • Ischemic preconditioning
  • Myocardial damage
  • Percutaneous coronary intervention
  • Tobacco

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{7e18e46c63d04a2fab43967d5cd3e0bb,
title = "Tobacco smoking protective effect via remote ischemic preconditioning on myocardial damage after elective percutaneous coronary intervention: Subanalysis of a randomized controlled trial",
abstract = "Background: Remote ischemic preconditioning (RIPC) is promising for preventing periprocedural myocardial damage (pMD) in patients undergoing percutaneous coronary intervention (PCI). However, the impact of RIPC on pMD on smokers is not well elucidated. The aim of this study was to investigate an association between tobacco smoking and RIPC on pMD in patients planning to undergo PCI. Methods: This study used data from a multicenter randomized controlled trial involving patients with stable angina who planned to undergo elective PCI. We analyzed data for 262 patients in the control (n = 133) and upper-limb RIPC (n = 129) groups, including 166 current or former smokers. The major outcome was the pMD incidence following PCI, with pMD defined as an elevated level of highly sensitive cardiac troponin T or a creatine kinase myocardial band 12 or 24 h after PCI. Results: The incidence of pMD was significantly lower in the upper-limb RIPC group than in the control group (28/83 patients [33.8{\%}] vs. 43/83 patients [51.8{\%}], respectively; p = 0.018). In a multiple logistic regression model, tobacco smoking was an independent predictor of interacting with and enhancing the effect of RIPC on reducing the incidence of pMD after PCI (regression coefficient, −0.4 [95{\%} confidence interval, −0.74 to −0.082]; p = 0.015). Conclusions: Tobacco smoking may have a beneficial effect on RIPC against pMD after PCI.",
keywords = "Ischemic preconditioning, Myocardial damage, Percutaneous coronary intervention, Tobacco",
author = "{RINC Study Collaborators} and Kentaro Ejiri and Toru Miyoshi and Kunihisa Kohno and Makoto Nakahama and Masayuki Doi and Mitsuru Munemasa and Masaaki Murakami and Atsushi Takaishi and Kazufumi Nakamura and Hiroshi Itoh",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.ijcha.2018.12.005",
language = "English",
volume = "22",
pages = "55--60",
journal = "IJC Heart and Vasculature",
issn = "2352-9067",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Tobacco smoking protective effect via remote ischemic preconditioning on myocardial damage after elective percutaneous coronary intervention

T2 - Subanalysis of a randomized controlled trial

AU - RINC Study Collaborators

AU - Ejiri, Kentaro

AU - Miyoshi, Toru

AU - Kohno, Kunihisa

AU - Nakahama, Makoto

AU - Doi, Masayuki

AU - Munemasa, Mitsuru

AU - Murakami, Masaaki

AU - Takaishi, Atsushi

AU - Nakamura, Kazufumi

AU - Itoh, Hiroshi

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Remote ischemic preconditioning (RIPC) is promising for preventing periprocedural myocardial damage (pMD) in patients undergoing percutaneous coronary intervention (PCI). However, the impact of RIPC on pMD on smokers is not well elucidated. The aim of this study was to investigate an association between tobacco smoking and RIPC on pMD in patients planning to undergo PCI. Methods: This study used data from a multicenter randomized controlled trial involving patients with stable angina who planned to undergo elective PCI. We analyzed data for 262 patients in the control (n = 133) and upper-limb RIPC (n = 129) groups, including 166 current or former smokers. The major outcome was the pMD incidence following PCI, with pMD defined as an elevated level of highly sensitive cardiac troponin T or a creatine kinase myocardial band 12 or 24 h after PCI. Results: The incidence of pMD was significantly lower in the upper-limb RIPC group than in the control group (28/83 patients [33.8%] vs. 43/83 patients [51.8%], respectively; p = 0.018). In a multiple logistic regression model, tobacco smoking was an independent predictor of interacting with and enhancing the effect of RIPC on reducing the incidence of pMD after PCI (regression coefficient, −0.4 [95% confidence interval, −0.74 to −0.082]; p = 0.015). Conclusions: Tobacco smoking may have a beneficial effect on RIPC against pMD after PCI.

AB - Background: Remote ischemic preconditioning (RIPC) is promising for preventing periprocedural myocardial damage (pMD) in patients undergoing percutaneous coronary intervention (PCI). However, the impact of RIPC on pMD on smokers is not well elucidated. The aim of this study was to investigate an association between tobacco smoking and RIPC on pMD in patients planning to undergo PCI. Methods: This study used data from a multicenter randomized controlled trial involving patients with stable angina who planned to undergo elective PCI. We analyzed data for 262 patients in the control (n = 133) and upper-limb RIPC (n = 129) groups, including 166 current or former smokers. The major outcome was the pMD incidence following PCI, with pMD defined as an elevated level of highly sensitive cardiac troponin T or a creatine kinase myocardial band 12 or 24 h after PCI. Results: The incidence of pMD was significantly lower in the upper-limb RIPC group than in the control group (28/83 patients [33.8%] vs. 43/83 patients [51.8%], respectively; p = 0.018). In a multiple logistic regression model, tobacco smoking was an independent predictor of interacting with and enhancing the effect of RIPC on reducing the incidence of pMD after PCI (regression coefficient, −0.4 [95% confidence interval, −0.74 to −0.082]; p = 0.015). Conclusions: Tobacco smoking may have a beneficial effect on RIPC against pMD after PCI.

KW - Ischemic preconditioning

KW - Myocardial damage

KW - Percutaneous coronary intervention

KW - Tobacco

UR - http://www.scopus.com/inward/record.url?scp=85058774870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058774870&partnerID=8YFLogxK

U2 - 10.1016/j.ijcha.2018.12.005

DO - 10.1016/j.ijcha.2018.12.005

M3 - Article

AN - SCOPUS:85058774870

VL - 22

SP - 55

EP - 60

JO - IJC Heart and Vasculature

JF - IJC Heart and Vasculature

SN - 2352-9067

ER -